Current Status of Urinary Biomarkers for Detection and Surveillance of Bladder Cancer

被引：67
作者：
Mbeutcha, Aurelie [1 ,2 ]
Lucca, Ilaria [1 ,3 ]
Mathieu, Romain [1 ,4 ]
Lotan, Yair [5 ]
Shariat, Shahrokh F. [1 ,5 ,6 ]
机构：
[1] Med Univ Vienna, Vienna Gen Hosp, Ctr Comprehens Canc, Dept Urol, A-1090 Vienna, Austria
[2] Univ Nice Sophia Antipolis, CHU Nice, Hop Archet 2, Dept Urol, F-06200 Nice, France
[3] CHU Vaudois, Dept Urol, CH-1010 Lausanne, Switzerland
[4] Rennes Univ Hosp, Dept Urol, F-35000 Rennes, France
[5] Univ Texas SW Med Ctr Dallas, Dept Urol, Dallas, TX 75235 USA
[6] Cornell Univ, Weill Cornell Med Coll, Dept Urol, New York, NY 10011 USA
来源：
UROLOGIC CLINICS OF NORTH AMERICA | 2016年 / 43卷 / 01期
关键词：
TRANSITIONAL-CELL CARCINOMA; IN-SITU HYBRIDIZATION; COMPLEMENT FACTOR-H; NUCLEAR-MATRIX PROTEIN-22; INVASIVE UROTHELIAL CARCINOMA; TRANSCRIPTASE MESSENGER-RNA; POLYMERASE-CHAIN-REACTION; PRIMARY-CARE PHYSICIANS; VOIDED-URINE; FOLLOW-UP;
D O I：
10.1016/j.ucl.2015.08.005
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
The standard of care for detection and surveillance of bladder cancer consists of cytology and cystoscopy, but both examinations suffer from many limitations, including issues related to accuracy, invasiveness, and cost. Several noninvasive methods for detection and surveillance of bladder cancer have been developed and urine-based biomarkers seem the most promising. This nonsystematic review critically analyzes the commercially available biomarkers and highlights some upcoming investigational biomarkers. To date, none of these biomarkers has sufficient validation to serve as a reliable alternative to cystoscopy.
引用
收藏
页码：47 / +
页数：17
相关论文
共 170 条
  • [1] [Anonymous], 2004, PATHOLOGY GENETICS T
  • [2] [Anonymous], ASIA PAC J CLIN ONCO
  • [3] [Anonymous], UROL ONCOL
  • [4] [Anonymous], UROL ONCOL
  • [5] Qualitative and quantitative detection of urinary human complement factor H-related protein (BTA stat and BTA TRAK) and fragments of cytokeratins 8, 18 (UBC rapid and UBCIRMA) as markers for transitional cell carcinoma of the bladder
    Babjuk, M
    Kostírová, M
    Mudra, K
    Pecher, S
    Smolová, H
    Pecen, L
    Ibrahim, Z
    Dvorácek, J
    Jarolím, L
    Novák, J
    Zima, T
    [J]. EUROPEAN UROLOGY, 2002, 41 (01) : 34 - 39
  • [6] EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013
    Babjuk, Marko
    Burger, Maximilian
    Zigeuner, Richard
    Shariat, Shahrokh F.
    van Rhijn, Bas W. G.
    Comperat, Eva
    Sylvester, Richard J.
    Kaasinen, Eero
    Boehle, Andreas
    Palou Redorta, Joan
    Roupret, Morgan
    [J]. EUROPEAN UROLOGY, 2013, 64 (04) : 639 - 653
  • [7] Outcomes of a Bladder Cancer Screening Program Using Home Hematuria Testing and Molecular Markers
    Bangma, Chris H.
    Loeb, Stacy
    Busstra, Martijn
    Zhu, Xiaoye
    El Bouazzaoui, Samira
    Refos, Jeanine
    Van der Keur, Kirstin A.
    Tjin, Stephen
    Franken, Conja G. A. M.
    van Leenders, Geert J. L. H.
    Zwarthoff, Ellen C.
    Roobol, Monique J.
    [J]. EUROPEAN UROLOGY, 2013, 64 (01) : 41 - 47
  • [8] Decision curve analysis assessing the clinical benefit of NMP22 in the detection of bladder cancer: secondary analysis of a prospective trial
    Barbieri, Christopher E.
    Cha, Eugene K.
    Chromecki, Thomas F.
    Dunning, Allison
    Lotan, Yair
    Svatek, Robert S.
    Scherr, Douglas S.
    Karakiewicz, Pierre I.
    Sun, Maxine
    Mazumdar, Madhu
    Shariat, Shahrokh F.
    [J]. BJU INTERNATIONAL, 2012, 109 (05) : 685 - 690
  • [9] Bartoletti R, 2005, ONCOL REP, V13, P531
  • [10] Multiplex polymerase chain reaction for microsatellite analysis of urine sediment cells: A rapid and inexpensive method for diagnosing and monitoring superficial transitional bladder cell carcinoma
    Bartoletti, Riccardo
    Cai, Tommaso
    Dal Canto, Maurizio
    Boddi, Vieri
    Nesi, Gabriella
    Piazzini, Mauro
    [J]. JOURNAL OF UROLOGY, 2006, 175 (06) : 2032 - 2037
12345678910